Monday, October 3, 2022

561.316.3330

Biotechnology News Magazine

ENPICOM Launches Versatile Display Aata Analysis Solution to Accelerate Antibody Selection While Maximizing Precision

Latest Posts

City of Hope to Accelerate Immunotherapy Research & Treatment Innovation with $15 Mil Gift from Ted Schwartz Family

Ted Schwartz, who is now cancer free, achieved complete remission at City of Hope in 2020 with the center's leading CAR T cell therapy after a 16-year battle with lymphoma, provided the gift to City of Hope to advance treatment options that offer better outcomes and quality of life for people living with cancer.

Neurocrine Biosciences Appoints Dr Ingrid Delaet as Chief Regulatory Officer

Prior to joining Neurocrine Biosciences, Dr Ingrid Delaet served as Senior Vice President, Regulatory Affairs at Intercept Pharmaceuticals, which she joined in 2016.

Astrea Bioseparations Introduces Nereus LentiHERO, a Fit-for-purpose Solution for Lentiviral Vector Purification

“We believe that AstreAdept will be a game-changer,” explained Astrea Bioseparations’ CEO Terry Pizzie. “Our approach was to rapidly develop and incorporate this material into the Nereus LentiHERO, a simple, fit-for-purpose device that radically transforms how lentivirus can be purified [in terms of speed, recovery, and efficiency].

At Pack Expo, Schreiner MediPharm to Debut Functional Labels Designed from More Sustainable Materials

Schreiner MediPharm advises he new label concepts are based on existing items in Schreiner MediPharm’s roster of functional labeling solutions.

ENPICOM, an innovative bioinformatics software company, announced the upcoming expansion of the capabilities of the IGX Platform to unlock seamless analysis of antibody panning data.

This major development will allow researchers to analyze antibody display data in an intuitive and visual way, easily perform multi-dataset comparisons, and identify a diverse set of enriched candidates with the best characteristics.

“Our customer-centric approach to product development gives us a close-up view of the complex analysis workflows required for antibody display screening and how a single, scalable tool can immensely improve speed of analysis and quality of the selected candidates.” said Jos Lunenberg, co-founder and Chief Executive Officer at ENPICOM. “Due to limited, inefficient workflows researchers often have to discard the vast majority of the available NGS data and focus on a small pool of the most frequent clones. We are launching the new IGX-Track App so that our customers can look beyond the tip of the iceberg and make informed decisions with a complete view of their data. Custom analysis workflows and visualizations can be created with a few clicks so scientists can simply select better antibodies faster.”

Enabling streamlined enrichment analysis

Display technologies empower antibody discovery by screening millions of candidates against potential targets. By including different panning round conditions and a variety of antigens, researchers can obtain a robust candidate pool with diverse binding profiles. However, complex analysis workflows – including operations like intersecting, joining, or subtracting datasets – that match the panning campaign design are needed to fully take advantage of the powerful combination of NGS and display screening.

The new IGX-Track App extends the antibody discovery capabilities of the IGX Platform and provides a fast, flexible way to discover a diverse set of enriched candidates with the best characteristics. Scientists can effortlessly compose enrichment analysis workflows that match the design of their panning campaigns and discover candidates that otherwise would have been overlooked.

Scientists using IGX-Track on the IGX Platform will be able to:

  • Track clones across panning rounds to identify highly enriched candidates through tabular views and interactive, user-defined visualizations.
  • Freely join, intersect, and subtract many datasets to match their panning campaign design.
  • Broaden their analysis beyond just the most frequent clones with the platform’s scalable, NGS-ready architecture.
  • Easily subtract irrelevant antibodies identified in control panning conditions from the candidates enriched on target.
  • Make fully informed choices, while avoiding bias, by overlaying accurate liability predictions, assay data, and more onto enrichment graphs.

The company will launch the new functionality at the Antibody Engineering and Therapeutics conference on June 8 in Amsterdam. Sign up here to watch their presentation and learn more.

Latest Posts

Learn More

spot_img

Subscribe

spot_img

Our Sister Publication

Medical Device News Magazine